摘要
目的:比较绞股蓝总苷片联合山楂精降脂片与阿托伐他汀钙片对高效抗逆转录病毒治疗(HAART)后血脂异常患者的疗效及安全性。方法:将60例HAART后血脂异常患者按2:1的比例随机分为试验组(40例)和对照组(20例)。试验组给予绞股蓝总苷片,每次1片(每片60mg),tid;山楂精降脂片,每次1片(每片60mg),tid。对照组给予阿托伐他汀钙片,每次1片(每片10mg),qd。2组均连续服药6周。检测服药前后患者血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、载脂蛋白A1(ApoA1)和载脂蛋白B(ApoB),比较2组患者各指标治疗前后差值、总有效率和不良反应。结果:治疗后试验组TC下降(0.26±0.59)mmol/L、LDL-C下降(0.13±0.58)mmol/L,对照组TC下降(0.83±0.84)mmol/L、LDL-C下降(0.69±0.94)mmol/L,2组比较差异均有统计学意义(P<0.05),而其余指标差值比较差异无统计学意义(P>0.05);试验组总有效率为72.50%,对照组总有效率为100.00%,2组比较差异有统计学意义(P<0.05)。试验组未见不良反应发生,对照组不良反应发生率为20.00%,2组比较差异有统计学意义(P<0.01)。结论:绞股蓝总苷片联合山楂精降脂片可在一定程度上改善血脂,虽疗效不及阿托伐他汀钙片,但安全性优于阿托伐他汀钙片。
OBJECTIVE：To compare the clinical effects between Jiaogulanzongdai Tablets combined with Shanzhajing Tablets and Atorvastation Calcium Tablets on HAART-associated dyslipidemia.METHODS：60 patients with HAART-associated dyslipidemia were randomly divided into the experimental group and the control group at the ratio of 2：1.All patients in the experimental group were given Jiaogulanzongdai Tablets（one tablet three times daily）and Shanzhajing Tablets（one tablet three times daily）for 6 weeks,and patients in the control group were given Atorvastation Calcium Tablets（one tablet daily）.Serum total cholesterol（TC）,triglyceride（TG）,low-density lipoprotein cholesterol（LDL-C）,high-density lipoprotein cholesterol（HDL-C）,apolipoprotein A1（ApoA1）,and apolipoprotein B（ApoB）were detected before and after the therapy.Then,the lipid changes after therapy,the clinical efficacy,and the adverse reactions were compared between the 2 groups.RESULTS：After therapy,the experimental group had a decrease of（0.26±0.59）mmol/L in TC,and a decrease of（0.13±0.58）mmol/L in LDL-C,compared with a decrease of（0.83±0.84）mmol/L in TC and a decrease of（0.69±0.94）mmol/L in LDL-C in the control group.There were significant differences in TC and LDL-C changes between the 2 groups（P0.05）,but other lipid changes had no difference（P0.05）.The experimental group had a 72.50% overall efficacy,compared with 100.00% of the control group（P0.05）.No adverse reactions were found in the experimental group,however,20.00% of patients in the control group had adverse reactions.There were significant differences in adverse reaction rates between the 2 groups.CONCLUSION：Jiaogulanzongdai Tablets combined with Shanzhajing Tablets is capable of improving blood lipid profiles,and is inferior to Atorvastation Calcium Tablets,but have better safety than Atorvastation Calcium Tablets.
出处
《中国药房》
CAS
CSCD
2013年第4期332-334,共3页
China Pharmacy
基金
广西壮族自治区卫生厅中医药科技专项(No.GZKZ10-065)
